Profile of prostanoid release following antigen challenge in vivo in the skin of man

W. A. Massey, W. C. Hubbard, Mark Chang Hwa Liu, A. Kagey-Sobotka, P. Cooper, L. M. Lichtenstein

Research output: Contribution to journalArticle

Abstract

We have previously characterized the kinetics of prostaglandin D2 (PGD2) production at cutaneous sites of allergic inflammation employing a blister-chamber model. In this study, a more complete profile of prostaglandins released in vivo was obtained. PGD2 release, as measured by radioimmunoassay and by combined gas chromatography-mass spectrometry, was evident within 1 h after antigen challenge with maximal levels occurring 3-4 h post-challenge. The 11-ketoreductase metabolite of PGD2, 9α,11β-prostaglandin F2 was present in blister fluid from three of six patients at the time of maximal levels of PGD2. The stable non-enzymatic hydrolysis product of prostacyclin, 6-ketoprostaglandin F(1α), was significantly elevated in blister fluid from five of six patients following antigen challenge. In these subjects, the levels of 6κ-PGF(1α) were highest in samples obtained 1 and 2 h after antigen challenge and remained significantly elevated until 5 h post-challenge. Levels of prostaglandin E2, prostaglandin F(2α) and thromboxane B2 did not vary significantly. These studies suggest that following antigen challenge two fatty-acid cyclo-oxygenase products of arachidonic acid are released, PGD2 and prostacyclin. The 11-ketoreductase metabolism of PGD2 to 9α,11β-PGF2 could represent a mechanism by which the biological effects of PGD2 are prolonged in cutaneous tissue. The presence of 6κ-PGF(1α) in the blister fluid suggests that significant prostacyclin release occurs as the result of antigen challenge and could represent a mechanism by which the prolonged microvascular response in cutaneous tissue may occur.

Original languageEnglish (US)
Pages (from-to)529-534
Number of pages6
JournalBritish Journal of Dermatology
Volume125
Issue number6
StatePublished - 1991

Fingerprint

Prostaglandin D2
Prostaglandins
Antigens
Skin
Blister
Prostaglandins F
Epoprostenol
Dinoprost
Thromboxane B2
Prostaglandin-Endoperoxide Synthases
Dinoprostone
Arachidonic Acid
Gas Chromatography-Mass Spectrometry
Radioimmunoassay
Hydrolysis
Inflammation

ASJC Scopus subject areas

  • Dermatology

Cite this

Massey, W. A., Hubbard, W. C., Liu, M. C. H., Kagey-Sobotka, A., Cooper, P., & Lichtenstein, L. M. (1991). Profile of prostanoid release following antigen challenge in vivo in the skin of man. British Journal of Dermatology, 125(6), 529-534.

Profile of prostanoid release following antigen challenge in vivo in the skin of man. / Massey, W. A.; Hubbard, W. C.; Liu, Mark Chang Hwa; Kagey-Sobotka, A.; Cooper, P.; Lichtenstein, L. M.

In: British Journal of Dermatology, Vol. 125, No. 6, 1991, p. 529-534.

Research output: Contribution to journalArticle

Massey, WA, Hubbard, WC, Liu, MCH, Kagey-Sobotka, A, Cooper, P & Lichtenstein, LM 1991, 'Profile of prostanoid release following antigen challenge in vivo in the skin of man', British Journal of Dermatology, vol. 125, no. 6, pp. 529-534.
Massey WA, Hubbard WC, Liu MCH, Kagey-Sobotka A, Cooper P, Lichtenstein LM. Profile of prostanoid release following antigen challenge in vivo in the skin of man. British Journal of Dermatology. 1991;125(6):529-534.
Massey, W. A. ; Hubbard, W. C. ; Liu, Mark Chang Hwa ; Kagey-Sobotka, A. ; Cooper, P. ; Lichtenstein, L. M. / Profile of prostanoid release following antigen challenge in vivo in the skin of man. In: British Journal of Dermatology. 1991 ; Vol. 125, No. 6. pp. 529-534.
@article{dd11e9f962964262bc1e741244a3eb2b,
title = "Profile of prostanoid release following antigen challenge in vivo in the skin of man",
abstract = "We have previously characterized the kinetics of prostaglandin D2 (PGD2) production at cutaneous sites of allergic inflammation employing a blister-chamber model. In this study, a more complete profile of prostaglandins released in vivo was obtained. PGD2 release, as measured by radioimmunoassay and by combined gas chromatography-mass spectrometry, was evident within 1 h after antigen challenge with maximal levels occurring 3-4 h post-challenge. The 11-ketoreductase metabolite of PGD2, 9α,11β-prostaglandin F2 was present in blister fluid from three of six patients at the time of maximal levels of PGD2. The stable non-enzymatic hydrolysis product of prostacyclin, 6-ketoprostaglandin F(1α), was significantly elevated in blister fluid from five of six patients following antigen challenge. In these subjects, the levels of 6κ-PGF(1α) were highest in samples obtained 1 and 2 h after antigen challenge and remained significantly elevated until 5 h post-challenge. Levels of prostaglandin E2, prostaglandin F(2α) and thromboxane B2 did not vary significantly. These studies suggest that following antigen challenge two fatty-acid cyclo-oxygenase products of arachidonic acid are released, PGD2 and prostacyclin. The 11-ketoreductase metabolism of PGD2 to 9α,11β-PGF2 could represent a mechanism by which the biological effects of PGD2 are prolonged in cutaneous tissue. The presence of 6κ-PGF(1α) in the blister fluid suggests that significant prostacyclin release occurs as the result of antigen challenge and could represent a mechanism by which the prolonged microvascular response in cutaneous tissue may occur.",
author = "Massey, {W. A.} and Hubbard, {W. C.} and Liu, {Mark Chang Hwa} and A. Kagey-Sobotka and P. Cooper and Lichtenstein, {L. M.}",
year = "1991",
language = "English (US)",
volume = "125",
pages = "529--534",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Profile of prostanoid release following antigen challenge in vivo in the skin of man

AU - Massey, W. A.

AU - Hubbard, W. C.

AU - Liu, Mark Chang Hwa

AU - Kagey-Sobotka, A.

AU - Cooper, P.

AU - Lichtenstein, L. M.

PY - 1991

Y1 - 1991

N2 - We have previously characterized the kinetics of prostaglandin D2 (PGD2) production at cutaneous sites of allergic inflammation employing a blister-chamber model. In this study, a more complete profile of prostaglandins released in vivo was obtained. PGD2 release, as measured by radioimmunoassay and by combined gas chromatography-mass spectrometry, was evident within 1 h after antigen challenge with maximal levels occurring 3-4 h post-challenge. The 11-ketoreductase metabolite of PGD2, 9α,11β-prostaglandin F2 was present in blister fluid from three of six patients at the time of maximal levels of PGD2. The stable non-enzymatic hydrolysis product of prostacyclin, 6-ketoprostaglandin F(1α), was significantly elevated in blister fluid from five of six patients following antigen challenge. In these subjects, the levels of 6κ-PGF(1α) were highest in samples obtained 1 and 2 h after antigen challenge and remained significantly elevated until 5 h post-challenge. Levels of prostaglandin E2, prostaglandin F(2α) and thromboxane B2 did not vary significantly. These studies suggest that following antigen challenge two fatty-acid cyclo-oxygenase products of arachidonic acid are released, PGD2 and prostacyclin. The 11-ketoreductase metabolism of PGD2 to 9α,11β-PGF2 could represent a mechanism by which the biological effects of PGD2 are prolonged in cutaneous tissue. The presence of 6κ-PGF(1α) in the blister fluid suggests that significant prostacyclin release occurs as the result of antigen challenge and could represent a mechanism by which the prolonged microvascular response in cutaneous tissue may occur.

AB - We have previously characterized the kinetics of prostaglandin D2 (PGD2) production at cutaneous sites of allergic inflammation employing a blister-chamber model. In this study, a more complete profile of prostaglandins released in vivo was obtained. PGD2 release, as measured by radioimmunoassay and by combined gas chromatography-mass spectrometry, was evident within 1 h after antigen challenge with maximal levels occurring 3-4 h post-challenge. The 11-ketoreductase metabolite of PGD2, 9α,11β-prostaglandin F2 was present in blister fluid from three of six patients at the time of maximal levels of PGD2. The stable non-enzymatic hydrolysis product of prostacyclin, 6-ketoprostaglandin F(1α), was significantly elevated in blister fluid from five of six patients following antigen challenge. In these subjects, the levels of 6κ-PGF(1α) were highest in samples obtained 1 and 2 h after antigen challenge and remained significantly elevated until 5 h post-challenge. Levels of prostaglandin E2, prostaglandin F(2α) and thromboxane B2 did not vary significantly. These studies suggest that following antigen challenge two fatty-acid cyclo-oxygenase products of arachidonic acid are released, PGD2 and prostacyclin. The 11-ketoreductase metabolism of PGD2 to 9α,11β-PGF2 could represent a mechanism by which the biological effects of PGD2 are prolonged in cutaneous tissue. The presence of 6κ-PGF(1α) in the blister fluid suggests that significant prostacyclin release occurs as the result of antigen challenge and could represent a mechanism by which the prolonged microvascular response in cutaneous tissue may occur.

UR - http://www.scopus.com/inward/record.url?scp=0026326655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026326655&partnerID=8YFLogxK

M3 - Article

VL - 125

SP - 529

EP - 534

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 6

ER -